The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells

International Journal of Oncology

Volumn 42, Issue 1, 2013, Pages 239-246

  Lysaght, Joanne ^a,b   Verma, Navin K ^b   Maginn, Elaina N ^a   Ryan, Jacqueline M ^a   Campiani, Giuseppe ^c   Zisterer, Daniela M ^b   Williams, D Clive ^b   Browne, Paul V ^a   Lawler, Mark P ^a   McElligott, Anthony M ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Acute lymphoblastic leukaemia; Adhesion; Apoptosis; Integrin; Microtubules

Indexed keywords

ALPHA4 INTEGRIN; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; CD18 ANTIGEN; CD19 ANTIGEN; INTEGRIN; OXAZEPINE DERIVATIVE; PYRROLOBENZOXAZEPINE 4 ACETOXY 5 (1NAPHTHYL)NAPHTHA PYRROLO[1,4] OXAZEPINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SPREADING; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MICROTUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; T LYMPHOCYTE;

APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; CELL PROLIFERATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTEGRINS; MICROTUBULES; OXAZEPINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRROLES; TUMOR CELLS, CULTURED;

EID: 84873469977     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1688     Document Type: Article

References (38)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004. (Pubitemid 38443417)
2. Pui CH, Robison LL and Look AT: Acute lymphoblastic leukaemia. Lancet 371: 1030-1043, 2008. (Pubitemid 351389536)
3. Pui CH and Evans WE: Drug therapy - treatment of acute lymphoblastic leukemia. N Engl J Med 354: 166-178, 2006. (Pubitemid 43076714)
4. Faderl S, O'Brien S, Pui CH, et al: Adult acute lymphoblastic leukemia concepts and strategies. Cancer 116: 1165-1176, 2010.
5. Mulligan JM, Greene LM, Cloonan S, et al: Identification of tubulin as the molecular target of proapoptotic pyrrolo-1, 5-benzoxazepines. Mol Pharmacol 70: 60-70, 2006.
6. Greene LM, Campiani G, Lawler M, Williams DC and Zisterer DM: BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1, 5-benzoxazepines. Mol Pharmacol 73: 419-430, 2008. (Pubitemid 351159212)
7. McElligott AM, Maginn EN, Greene LM, et al: The novel tubulin-targeting agent pyrrolo-1, 5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res 69: 8366-8375, 2009.
8. Nathwani SM, Butler S, Fayne D, et al: Novel microtubule-targeting agents, pyrrolo-1, 5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemother Pharmacol 66: 585-596, 2010.
9. Forde JC, Maginn EN, McNamara G, et al: Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro. Cancer Biol Ther 11: 421-428, 2011.
10. Maginn EN, Browne PV, Hayden P, et al: PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. Br J Cancer 104: 281-289, 2011.
11. Bright SA, McElligott AM, O'Connell JW, et al: Novel pyrrolo-1, 5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Br J Cancer 102: 1474-1482, 2010.
12. Vilpo JA, Koski T and Vilpo LM: Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur J Haematol 65: 370-378, 2000.
13. Beswick RW, Ambrose HE and Wagner SD: Nocodazole, a microtubule depolymerising agent, induces apoptosis of chronic lymphocytic leukaemia cells associated with changes in Bcl-2 phosphorylation and expression. Leuk Res 30: 427-436, 2006. (Pubitemid 43254964)
14. Moon EY and Lerner A: Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res 62: 5711-5719, 2002. (Pubitemid 35204726)
15. Aisenberg AC and Wilkes B: Studies on suppression of immune responses by periwinkle alkaloids vincristine + vinblastine. J Clin Invest 43: 2394-2403, 1964.
16. Park SJ, Shim WH, Ho DS, et al: A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348: 1537-1545, 2003. (Pubitemid 36437930)
17. Manabe A, Murti KG, Coustansmith E, et al: Adhesion-dependent survival of normal and leukemic human-B lymphoblasts on bone-marrow stromal cells. Blood 83: 758-766, 1994. (Pubitemid 24043737)
18. De la Fuente MT, Casanova B, Moyano JV, et al: Engagement of alpha 4 beta 1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 71: 495-502, 2002.
19. Scimone ML, Alfantis I, Apostolou I, von Boehmer H and von Andrian UH: A multistep adhesion cascade for lymphoid progenitor cell homing to the thymus. Proc Natl Acad Sci USA 103: 7006-7011, 2006.
20. Cox D, Brennan M and Moran N: Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 9: 804-820, 2010.
21. Astier AL, Svoboda M, Hinds E, De Beaumont R, Munoz O and Freedman AS: Integrins regulate survival of pre-B-ALL cells through differential IAP and caspase-7 ubiquitination and degradation. Leukemia 18: 873-875, 2004. (Pubitemid 38500208)
22. Streuli CH and Akhtar N: Signal co-operation between integrins and other receptor systems. Biochem J 418: 491-506, 2009.
23. Zhou XM, Li JX and Kucik DF: The microtubule cytoskeleton participates in control of beta(2) integrin avidity. J Biol Chem 276: 44762-44769, 2001.
24. Verma NK, Dempsey E, Conroy J, et al: A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin. J Mol Med 86: 457-469, 2008.
25. Campiani G, Nacci V, Fiorini I, et al: Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific 'peripheral-type' benzodiazepine receptor ligands. J Med Chem 39: 3435-3450, 1996. (Pubitemid 26307848)
26. McGee MM, Gemma S, Butini S, et al: Pyrrolo[1, 5]benzoxa(thia)zepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target. J Med Chem 48: 4367-4377, 2005. (Pubitemid 40884939)
27. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA and McCarthy RE: Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18: 522-529, 1965.
28. Dhut S, Gibbons B, Chaplin T and Young BD: Establishment of a lymphoblastoid cell-line, Sd-1, expressing the p190 bcr-abl chimeric protein. Leukemia 5: 49-55, 1991.
29. Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39-51, 1995.
30. Verma NK, Dourlat J, Davies AM, et al: STAT3-stathmin interactions control microtubule dynamics in migrating T-cells. J Biol Chem 284: 12349-12362, 2009.
31. Mohamed BM, Verma NK, Davies AM, et al: Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine 7: 1181-1195, 2012.
32. Mohamed BM, Verma NK, Prina-Mello A, et al: Activation of stress-related signalling pathway in human cells upon SiO2 nanoparticles exposure as an early indicator of cytotoxicity. J Nanobiotechnology 9: 29, 2011.
33. McGrath LB, Onnis V, Campiani G, Williams DC, Zisterer DM and McGee MM: Caspase-activated DNase (CAD)-independent oligonucleosomal DNA fragmentation in chronic myeloid leukaemia cells; a requirement for serine protease and Mn2+-dependent acidic endonuclease activity. Apoptosis 11: 1473-1487, 2006. (Pubitemid 44253666)
34. Whipple RA, Matrone MA, Cho EH, et al: Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement. Cancer Res 70: 8127-8137, 2010.
35. Tiruppathi C, Malik AB, Del Vecchio PJ, Keese CR and Giaever I: Electrical method for detection of endothelial cell shape change in real time: assessment of endothelial barrier function. Proc Natl Acad Sci USA 89: 7919-7923, 1992.
36. Von Andrian UH and Mackay CR: Advances in immunology: T-cell function and migration - two sides of the same coin. N Engl J Med 343: 1020-1033, 2000.
37. Matsunaga T, Takemoto N, Sato T, et al: Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9: 1158-1165, 2003. (Pubitemid 37173700)
38. Shalapour S, Hof J, Kirschner-Schwabe R, et al: High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica 96: 1627-1635, 2011.